Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

15.03
-0.1000-0.66%
Volume:231.31K
Turnover:3.50M
Market Cap:1.28B
PE:-3.94
High:15.45
Open:15.14
Low:14.85
Close:15.13
52wk High:62.75
52wk Low:5.95
Shares:85.11M
Float Shares:55.47M
Volume Ratio:0.60
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:2.99
PE(LYR):-4.26

Loading ...

MoonLake Immunotherap Is Maintained at Buy by Clear Street

Dow Jones
·
Mar 11

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)

TIPRANKS
·
Mar 11

MoonLake price target raised to $70 from $45 at Clear Street

TIPRANKS
·
Mar 11

MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed?

Simply Wall St.
·
Mar 03

MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Mar 02

RBC Capital Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Mar 02

MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright

TIPRANKS
·
Mar 02

MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $40 From $32

THOMSON REUTERS
·
Mar 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF)

TIPRANKS
·
Mar 02

MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs

TIPRANKS
·
Feb 26

MoonLake Immunotherap Price Target Maintained With a $25.00/Share by Needham

Dow Jones
·
Feb 26

MoonLake posts FY 2025 interest expense of USD 7.2 million

Reuters
·
Feb 25

MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer

TIPRANKS
·
Feb 24

MoonLake Immunotherapeutics : Leerink Partners Raises Target Price to $24 From $20

THOMSON REUTERS
·
Feb 24

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
Feb 24

Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept

MT Newswires Live
·
Feb 24

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Feb 24

BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase

Reuters
·
Feb 23

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk

Reuters
·
Feb 23